JCRB3047 MK-19
Cell information
Cell type:human mutant cell repository from Kyoto University (View Pricing Information)
| JCRB No. | JCRB3047 | Cell Name | MK-19 |
|---|---|---|---|
| Profile | Congenital anomaly (Mutant karyotype) 18-trisomy | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | Age | ||
| Identity | available | Tissue for Primary Cancer | |
| Case history | Congenital anomaly (Mutant karyotype) | Metastasis | |
| Tissue Metastasized | Genetics | Trisomy 18 | |
| Life Span | Crisis PDL | ||
| Morphology | Character | ||
| Classify | primary | Established by | SASAKI M. |
| Registered by | Radiation Biology Center, Kyoto University | Regulation for Distribution | |
| Comment | Year | ||
| Medium | RPMI1640 medium with 20% fetal bovine serum | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. (Split ratio=1/3) |
| Cell Number on Passage | Race | ||
| CO2 Conc. | Tissue Sampling | ||
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Movies |
|---|
|
|
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB3047 | Cell Name | MK-19 |
|---|---|---|---|
| LOT No. | 08012017 | Lot Specification | distribution |
| Medium | RPMI1640 medium (GIBCO) with 20% fetal bovine serum (SIGMA, Cat#172012, Lot#12J396, nonHI ) | Temperature | 37 C |
| Cell Density at Seeding | 2-4x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin (GIBCO) and 0.02% EDTA. (Split ratio=1/3) |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 1.38x10^6 |
| Viability at cell freezing (%) | 95.6 | Antibiotics Used | free |
| Passage Number | p7 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11,12 D13S317:9,10 D7S820:8,11 D16S539:9 VWA:14,17 TH01:6,9 AM:X TPOX:8,11 CSF1PO:9,12 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | NT | Additional information | Correct passage number is p7,but printed in the ampoule as p6 |
| Cell No. | JCRB3047 | Cell Name | MK-19 |
|---|---|---|---|
| LOT No. | 07272017 | Lot Specification | distribution |
| Medium | RPMI1640 medium (GIBCO) with 20% fetal bovine serum (SIGMA, Cat#172012, Lot#12J396, nonHI ) | Temperature | 37 C |
| Cell Density at Seeding | 2-4x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25% trypsin (GIBCO) and 0.02% EDTA. (Split ratio=1/3) |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 1.27x10^6 |
| Viability at cell freezing (%) | 87.7 | Antibiotics Used | free |
| Passage Number | p8 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11,12 D13S317:9,10 D7S820:8,11 D16S539:9 VWA:14,17 TH01:6,9 AM:X TPOX:8,11 CSF1PO:9,12 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | CELLBANKER1((Nihon Zenyaku Industries) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | NT | Additional information |